Cancer Research, the medical journal of the American Association for Cancer Research (AACR), has published a fundamental scientific paper disclosing the mechanism of action of the ImmuPharma’s cancer compound IPP-204106.
According to the research, the IPP-204106 programme, which is a potential treatment for various cancers, involves the development of synthetic peptides, Nucants, which target surface nucleolin with very high affinity and selectivity.
The publication was entitled “Nucleolin targeting impairs the progression of pancreatic cancer and promotes the normalization of tumour vasculature” and was authored by a number of researchers working within ImmuPharma on the Company’s Cancer programme.
The study for this compound, N6L has found that Nucleolin inhibition is a new anti-cancer therapeutic strategy that has been shown to dually normalise tumour vasculature and reduce its volume.
As a result, it has the potential to improve dramatically the delivery and efficacy of existing chemotherapeutic drugs, and in particular, for difficult-to-treat tumours such as Pancreatic cancer
Dr. Robert Zimmer, MD, PhD, ImmuPharma’s President and head of R&D explains: “The publication of the mechanism of action of the Nucants in Cancer Research is a validation of this novel concept in the treatment of cancer we have been developing in partnership with our collaboration partner, CNRS. It relies on the modulating effect of the Nucants on angiogenesis, the mechanism which controls the formation of micro vessels. Generally, the tumour generated micro vessels are of poor quality and offer a poor supply of blood and oxygen to the tumour. As a consequence, it makes the tumour much more resistant to cytotoxic drugs. By modulating the tumour micro vessels Nucants ameliorate the blood flow, allow a better oxygen supply and increase the intra-tumoural cytotoxic drug concentration. About threefold increase of cytotoxic drug concentration and threefold decrease in tumour size have been observed in preclinical studies. The intended treatment scheme is to pre-treat the patient with Nucant and then deliver the standard dose of cytotoxic drug, Gemcitabin for example in pancreatic cancer.
This is the second time that we have been acknowledged by the ACCR. The first in 2011 when our Cancer compound was chosen to be on the cover of the journal disclosing the specific binding to nucleolin and therefore to tumour cells by the Nucants. It is a pleasing validation of years of research by our scientific team and collaborators and gives us further confidence in the long term potential of our Cancer programme, this compound and its unique mechanism of action”.